Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
3.715
-0.155 (-4.01%)
Mar 20, 2026, 1:45 PM EDT - Market open
Iovance Biotherapeutics Stock Forecast
Stock Price Forecast
The 9 analysts that cover Iovance Biotherapeutics stock have a consensus rating of "Buy" and an average price target of $9.11, which forecasts a 145.22% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $17.
Price Target: $9.11 (+145.22%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Iovance Biotherapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 4 | 5 | 5 | 5 | 6 | 5 |
| Hold | 3 | 3 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 12 | 12 | 12 | 13 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Maintains $2 → $4 | Hold | Maintains | $2 → $4 | +7.67% | Mar 5, 2026 |
| Citizens | Citizens | Hold → Buy Upgrades $5 | Hold → Buy | Upgrades | $5 | +34.59% | Mar 3, 2026 |
| Barclays | Barclays | Buy Maintains $10 → $11 | Buy | Maintains | $10 → $11 | +196.10% | Feb 25, 2026 |
| Citizens | Citizens | Hold → Buy Upgrades $5 | Hold → Buy | Upgrades | $5 | +34.59% | Feb 25, 2026 |
| Barclays | Barclays | Buy Maintains $9 → $10 | Buy | Maintains | $9 → $10 | +169.18% | Dec 17, 2025 |
Financial Forecast
Revenue This Year
393.00M
from 263.50M
Increased by 49.14%
Revenue Next Year
596.16M
from 393.00M
Increased by 51.69%
EPS This Year
-0.51
from -1.09
EPS Next Year
-0.23
from -0.51
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 451.5M | 755.0M | |||
| Avg | 393.0M | 596.2M | |||
| Low | 333.2M | 431.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 71.3% | 92.1% | |||
| Avg | 49.1% | 51.7% | |||
| Low | 26.5% | 9.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.37 | -0.04 | |||
| Avg | -0.51 | -0.23 | |||
| Low | -0.64 | -0.38 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.